NO5B1A: Benzodiazepines with intermediate/long-term action.The classification of drugs used for anxiety and insomnia falls under the therapeutic group “NO5B Anxiolytics, sedatives and hypnotics”3, in which there are a large number of commercial brands which are divided into the following subgroups: It is worth considering that in 1987, according to the census, Spain had a population of some 38 million inhabitants. In 1987, 27 years ago, more than 18 million packages containing benzodiazepines as the main ingredient were taken in Spain2. Insomnia is associated with depressive or anxiety disorders in 90% of cases.īenzodiazepines were introduced in the pharmaceutical market in Spain in the 1960s, since when their use has grown constantly due to their anxiolytic, hypnotic and sedative properties and their broad safety margin. The prevalence of insomnia is around 20%, increases with age and is more common in women (23.9%) than men (17.6%). Insomnia refers to difficulty in getting to sleep or remaining asleep, waking early or frequently during the night, and it, too, is not always pathological and does not always need treatment. Anxiety is a normal, useful and common reaction when we are faced with compromising situations, and not just on a mental level, as it increases our state of alertness and activates our defense mechanisms. Wakefulness, inability to fall asleep or remain asleep.Īlthough these definitions are not medical, they demonstrate that anxiety and insomnia are not always pathological.
The distress that tends to accompany many diseases, especially certain neuroses, giving its sufferers no relief. A state of agitation, uneasiness or apprehension. According to the Royal Spanish Language Academy, anxiety1 has two definitions:1.
0 kommentar(er)
